Since 2012, the number of mergers and acquisitions in the pharmaceutical industry has continued to grow, reaching 283 global transactions by 2015.
Since 2016, the pace of mergers and acquisitions of global pharmaceutical companies has slowed down, with a significant decline. Perhaps due to the 2016 us presidential election, in the fourth quarter of 2016 since the 2012 presidential election is the slowest period of mergers and acquisitions, including drug pricing, drug tax and insurance will depend on the election results.
There were 184 transactions in 2016, down from 283 in 2015. At the same time, the total value of the transaction has been greatly reduced, with the total value of the transactions in 2016 only $98.7 billion, down 47.7% from the $1889 billion in 2015.
Some of the top acquisitions in 2016 include:
On April 28th, AbbVie bought Stemcentrx, a cancer drug company, for $9.8 billion.
On February 10, Mylan bought Medabuy for $7.2 billion;
On December 15, Lonza bought the company for $5.5 billion;
On May 16th, Pfizer bought Anacor for $4.5 billion;
On Sept. 20, Allergan acquired Tobira for $1.7 billion;
On August 24th the company bought AstraZeneca's antibiotics business for $1.5 billion.
In 2017, the acquisition process of major pharmaceutical companies continues to slow down. According to the incomplete statistics of pharmaceutical geography, the acquisition and acquisition trend of major pharmaceutical companies in the first half of the year mainly includes:
· on January 9, wutian bought Ariad, a us pharmaceutical company, for $5.2 billion
-- takata received two new targeted treatment drugs for Ariad.
· on January 19, lilly paid $960m for biotech company CoLucid
-- eli lilly's core asset is a 5HT1F receptor agonist, Lasmiditan, intended to improve its pain medication product line
· on January 26, Johnson & Johnson announced it was buying Actelion for $30 billion
-- Actelion's PAH drugs can form a complementary combination with the products of Johnson pharmaceuticals. Johnson & Johnson will also have products or commercial rights in other areas of the company's disease. It is expected to add $1.3 billion in sales to Johnson & Johnson in 2017.
On April 24th, Becton Dickinson paid $24 billion for CR Bard.
-- bidi healthcare is expected to be among the top five in the world, and more than Siemens
On April 25, fresenius paid 670 million euros for Merck's bio-generics business, while $4.75 billion bought Akorn, an American generic drug company
-- fresenius' biosimilars business sector has been perfected
· on May 17, seemer will buy Patheon, a pharmaceutical research and development outsourcing company, for $7.2 billion
-- semer flew into the $40 billion CDMO market
On May 19, anstay completed an 800m purchase of Ogeda
-- ansteen to get menopause drug fezolinetant, will help expand the later pipeline assets, and will help it to grow in the medium to long term.
The path of Chinese drug companies' overseas acquisitions has not stopped. Many Chinese native companies or through mergers and acquisitions at sea to accelerate the global industrial chain integration, or through international certification product out, or around the world to seek diversified cooperation into the global market.
The value of mergers and acquisitions has also increased year by year: the highest transaction price in 2017 reached 5.68 billion yuan. Although there is still a gap between the drug giants and the pharmaceutical giants, it also sees local drug companies aggressively expanding their overseas market ambitions.
Us $819 million
On January 9, tricell group with Valeant Canada (spirit) pharmaceutical acquisition agreement in San Francisco, tricell group for $819 million (RMB 5.68 billion) to buy Valeant Canada (spirit) pharmaceutical, biological pharmaceutical companies in the United States Dendreon100 % equity, and the Chinese buying American drug biggest trading records.
After the acquisition, sanpower will become the world's first owner of the Provenge of prostate cancer cell immunotherapy.
Us $605 million
On June 20th, the Yangtze river industrial fund joint handler, capital and human medicine, complete the subdivision of the pharmaceutical industry leading RiteDose company acquisitions, mergers and acquisitions involving $605 million of funds, will introduce Blow - Fill - Seal (BFS, bottle filling and sealing) technology.
After the acquisition, it is expected to fill the gap of BFS core technology in the country's 13th five-year plan.
4 billion
Born June 8, the pharmaceutical industry have accepted by Defoe capital, boc investment, CDH investments, shang capital, bo win Chinese consortium of venture jointly sponsored the roughly $605 million takeover bid. The drug is developed in the United States, with products including cancer, infectious diseases, and cardiovascular diseases, which focus on the pharmaceutical market.
1.1 billion
On May 2, chutian investment in the state of chu, hunan province, a $1.1 billion acquisition of German pharmaceutical company Romaco.
After the completion of the merger, chutian technology and Romaco will directly form complementary products online, and will also broaden the market scope of the chutian technology.
837 million
On June 19, the company announced plans to buy a 100% stake in Italian Newchem S.P.A. and Effechem S.R.L. for 110 million euros (837 million yuan).
Newchem specializes in the development, production and marketing of steroids and hormonal drugs. Effechem mainly engages in various sales activities in the pharmaceutical industry. This acquisition is one of the important measures to implement the international development strategy of pharmaceutical pharmaceutical. |
